Daniel Louis Hertz

59PUBLICATIONS
139CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Oct 12, 2026
Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants.

|Aug 04, 2026
Knowledge and Attitudes on Germline Pharmacogenomic Testing Among Clinical Oncologists.

|Apr 30, 2026
Lipidomic Predictors of Paclitaxel-Induced Peripheral Neuropathy.

|Apr 28, 2026
Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.

|Feb 27, 2026
Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.

Nam Nguyen-Hoang, Kelly Nugent, Sophia Jaso

|Dec 05, 2025
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

Nadine Norton, Nicholas B Larson, Gregory D Jenkins

Pageof 10

Frequent Collaborators

10 joint publications

N Lynn Henry

6 joint publications

Amy L Pasternak

5 joint publications

J Kevin Hicks

5 joint publications

Jai N Patel